Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian F Tannock

Showing results (11-20 of 240) with videos related to

Pageof 24
Sort By:
Ecancermedicalscience|March 4, 2022
Clinical research in oncology: in memory of Professor Gordon McVieIan F Tannock
The Lancet. Oncology|December 17, 2016
Can modelling of PSA dynamics accelerate drug development for prostate cancer?Ian F Tannock
The New England Journal of Medicine|October 31, 2017
Abiraterone in Metastatic Prostate CancerIan F Tannock
Lancet (London, England)|April 20, 2002
Eradication of a disease: how we cured symptomless prostate cancerIan F Tannock
Clinical Advances in Hematology & Oncology : H&O|June 22, 2022
Is the use of progression-free survival a valid endpoint for trials of drug combinations in oncology?Ian F Tannock
Cancer Cell|March 24, 2012
Targeting tumor architecture to favor drug penetration: a new weapon to combat chemoresistance in pancreatic cancer?Man Yu, Ian F Tannock
Cancer Research|May 3, 2003
Repopulation in murine breast tumors during and after sequential treatments with cyclophosphamide and 5-fluorouracilLicun Wu, Ian F Tannock
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2011
Chemotherapy-based treatment for castration-resistant prostate cancerBostjan Seruga, Ian F Tannock
Journal of the National Cancer Institute|December 7, 2010
When are "positive" clinical trials in oncology truly positive?Alberto Ocana, Ian F Tannock
The Lancet. Oncology|March 1, 2008
Trials in palliative treatment--have the goal posts been moved?Peter Kirkbride, Ian F Tannock
Pageof 24

Showing results (11-20 of 240) with videos related to

Sort By:
Pageof 24
Ecancermedicalscience|March 4, 2022
Clinical research in oncology: in memory of Professor Gordon McVieIan F Tannock
The Lancet. Oncology|December 17, 2016
Can modelling of PSA dynamics accelerate drug development for prostate cancer?Ian F Tannock
The New England Journal of Medicine|October 31, 2017
Abiraterone in Metastatic Prostate CancerIan F Tannock
Lancet (London, England)|April 20, 2002
Eradication of a disease: how we cured symptomless prostate cancerIan F Tannock
Clinical Advances in Hematology & Oncology : H&O|June 22, 2022
Is the use of progression-free survival a valid endpoint for trials of drug combinations in oncology?Ian F Tannock
Cancer Cell|March 24, 2012
Targeting tumor architecture to favor drug penetration: a new weapon to combat chemoresistance in pancreatic cancer?Man Yu, Ian F Tannock
Cancer Research|May 3, 2003
Repopulation in murine breast tumors during and after sequential treatments with cyclophosphamide and 5-fluorouracilLicun Wu, Ian F Tannock
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2011
Chemotherapy-based treatment for castration-resistant prostate cancerBostjan Seruga, Ian F Tannock
Journal of the National Cancer Institute|December 7, 2010
When are "positive" clinical trials in oncology truly positive?Alberto Ocana, Ian F Tannock
The Lancet. Oncology|March 1, 2008
Trials in palliative treatment--have the goal posts been moved?Peter Kirkbride, Ian F Tannock
Pageof 24